CN101460630B - He4与其它生化标记物在卵巢癌评估中的应用 - Google Patents

He4与其它生化标记物在卵巢癌评估中的应用 Download PDF

Info

Publication number
CN101460630B
CN101460630B CN200780007130.6A CN200780007130A CN101460630B CN 101460630 B CN101460630 B CN 101460630B CN 200780007130 A CN200780007130 A CN 200780007130A CN 101460630 B CN101460630 B CN 101460630B
Authority
CN
China
Prior art keywords
he4a
patient
antibody
ovarian cancer
smrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780007130.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101460630A (zh
Inventor
理查德·摩尔
伊丽莎白·萨默斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio America Inc
Original Assignee
Fujirebio America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio America Inc filed Critical Fujirebio America Inc
Priority to CN201610512072.3A priority Critical patent/CN106124765A/zh
Publication of CN101460630A publication Critical patent/CN101460630A/zh
Application granted granted Critical
Publication of CN101460630B publication Critical patent/CN101460630B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN200780007130.6A 2006-01-04 2007-01-04 He4与其它生化标记物在卵巢癌评估中的应用 Active CN101460630B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610512072.3A CN106124765A (zh) 2006-01-04 2007-01-04 He4与其它生化标记物在卵巢癌评估中的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75613106P 2006-01-04 2006-01-04
US60/756,131 2006-01-04
PCT/US2007/000216 WO2007081768A2 (en) 2006-01-04 2007-01-04 Use of he4 and other biochemical markers for assessment of ovarian cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610512072.3A Division CN106124765A (zh) 2006-01-04 2007-01-04 He4与其它生化标记物在卵巢癌评估中的应用

Publications (2)

Publication Number Publication Date
CN101460630A CN101460630A (zh) 2009-06-17
CN101460630B true CN101460630B (zh) 2016-08-10

Family

ID=38256906

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200780007052.XA Active CN101473041B (zh) 2006-01-04 2007-01-04 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
CN201610512072.3A Pending CN106124765A (zh) 2006-01-04 2007-01-04 He4与其它生化标记物在卵巢癌评估中的应用
CN200780007130.6A Active CN101460630B (zh) 2006-01-04 2007-01-04 He4与其它生化标记物在卵巢癌评估中的应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN200780007052.XA Active CN101473041B (zh) 2006-01-04 2007-01-04 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
CN201610512072.3A Pending CN106124765A (zh) 2006-01-04 2007-01-04 He4与其它生化标记物在卵巢癌评估中的应用

Country Status (7)

Country Link
US (8) US20070286865A1 (enExample)
EP (6) EP3026119B1 (enExample)
JP (3) JP5221381B2 (enExample)
CN (3) CN101473041B (enExample)
ES (2) ES2748397T3 (enExample)
PL (1) PL2982761T3 (enExample)
WO (2) WO2007081768A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5604100A (en) * 1999-06-09 2000-12-28 Moltech Corporation Methods of preparing a microporous article
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2006119155A2 (en) * 2005-05-02 2006-11-09 The Brigham And Women's Hospital, Inc. Diagnostic serum antibody profiling
CN101473041B (zh) 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
CA2637446A1 (en) * 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
US8329399B2 (en) 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
WO2008112514A1 (en) * 2007-03-09 2008-09-18 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
ES2411921T3 (es) * 2007-03-29 2013-07-09 Fujirebio Diagnostics, Inc. Uso de HE4 para la evaluación de cánceres de mama
CN101377502A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 肿瘤相关抗原72-4化学发光免疫分析测定试剂盒及其制备方法
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
EP2609429B1 (en) * 2010-08-26 2017-09-20 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
BR112013021056B1 (pt) 2011-02-17 2022-03-29 Pujirebio Diagnostics, Inc Anticorpo monoclonal, kit, e, método para diagnosticar um indivíduo com câncer ovariano
KR20140024860A (ko) * 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease
DE102012205164B4 (de) 2012-03-29 2021-09-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Projektionsdisplay und Verfahren zur Projektion virtueller Bilder
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
CN102890083B (zh) * 2012-09-28 2016-08-10 辽宁科骏生物有限公司 化学发光底物溶液和含其的试剂盒及应用其的检测方法
CN104655858B (zh) * 2015-03-12 2016-02-10 德迈基生物技术（北京）有限公司 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
RU2585959C1 (ru) * 2015-06-22 2016-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики асцитно-инфильтративной формы рака яичников и абдоминального туберкулёза
US10267802B2 (en) 2015-09-23 2019-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosis and diagnosis of ovarian cancer
RU2624508C1 (ru) * 2016-06-29 2017-07-04 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования длительности ремиссии у больных раком вульвы
TW202434291A (zh) 2016-07-08 2024-09-01 美商建南德克公司 人類副睪蛋白4 (he4)用於評定癌症治療反應性之用途
WO2021216670A1 (en) 2020-04-21 2021-10-28 University Of Rochester Inhibitors of human epididymus protein 4
CN111781364B (zh) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
US20240385195A1 (en) * 2022-04-08 2024-11-21 Ajou University Industry-Academic Cooperation Foundation Peptide for detecting ca125 and use thereof
WO2023195629A1 (ko) * 2022-04-08 2023-10-12 아주대학교산학협력단 He4 검출용 펩타이드 및 그 용도
CN120254284B (zh) * 2025-06-03 2025-08-22 杭州广科安德生物科技有限公司 一种用于预测子宫内膜癌复发或转移风险的生物标志物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
JP4813661B2 (ja) 1999-02-26 2011-11-09 パシフィック ノースウエスト リサーチ インスティテュート 癌を診断するための方法および組成物
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US20020182619A1 (en) * 2000-11-08 2002-12-05 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
NZ562192A (en) * 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
JP2006515065A (ja) * 2002-08-16 2006-05-18 ディシジョン バイオマーカーズ インコーポレイテッド 蛍光配列の読み取り
JP2006514284A (ja) * 2003-02-05 2006-04-27 サイファージェン バイオシステムズ インコーポレイテッド 羊水内環境の非侵襲性評価
EP1633784B1 (en) * 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN1266475C (zh) * 2003-06-05 2006-07-26 马旭 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
DE602006002809D1 (de) * 2005-02-16 2008-10-30 Dana Farber Cancer Inst Inc Verfahren zur erkennung eines ovarialkarzinoms
WO2007002264A2 (en) * 2005-06-22 2007-01-04 The Johns Hopkins University Biomarker for ovarian cancer: ctap3-related proteins
CA2611173C (en) * 2005-06-24 2019-11-12 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
CN101473041B (zh) 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用

Also Published As

Publication number Publication date
WO2007081768A2 (en) 2007-07-19
EP3026119B1 (en) 2019-09-18
US20200182878A1 (en) 2020-06-11
PL2982761T3 (pl) 2018-03-30
EP2982761B1 (en) 2017-10-04
US20240288434A1 (en) 2024-08-29
US20200292549A1 (en) 2020-09-17
JP5164855B2 (ja) 2013-03-21
JP5221381B2 (ja) 2013-06-26
CN101473041A (zh) 2009-07-01
US20240230652A9 (en) 2024-07-11
EP2420576A3 (en) 2012-03-14
JP2009521953A (ja) 2009-06-11
EP2423321A2 (en) 2012-02-29
ES2650244T3 (es) 2018-01-17
EP3026119A1 (en) 2016-06-01
JP5711196B2 (ja) 2015-04-30
HK1219514A1 (en) 2017-04-07
US20180156805A1 (en) 2018-06-07
EP1969136A4 (en) 2009-04-15
US20080020473A1 (en) 2008-01-24
US20070286865A1 (en) 2007-12-13
CN101473041B (zh) 2017-11-14
US20240133889A1 (en) 2024-04-25
EP2982761A1 (en) 2016-02-10
WO2007081768A3 (en) 2008-04-24
JP2013050457A (ja) 2013-03-14
JP2009522578A (ja) 2009-06-11
EP1969136A2 (en) 2008-09-17
WO2007081767A3 (en) 2008-04-24
CN106124765A (zh) 2016-11-16
EP2420576A2 (en) 2012-02-22
CN101460630A (zh) 2009-06-17
US20180180620A1 (en) 2018-06-28
EP2423321A3 (en) 2012-03-14
EP1846768A2 (en) 2007-10-24
ES2748397T3 (es) 2020-03-16
WO2007081767A2 (en) 2007-07-19
EP1846768A4 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
CN101460630B (zh) He4与其它生化标记物在卵巢癌评估中的应用
JP5144742B2 (ja) 乳がんの評価のためのｈｅ４の使用
RU2678135C1 (ru) Композиция и способ для детектирования злокачественного неопластического заболевания
HK1225411A (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1225411A1 (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1225411B (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1166109A (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1133445A (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
HK1133445B (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
HK1219514B (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
HK1166110A (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
HK1136630B (en) Use of he4 for assessment of breast cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant